The price of Xeljanz (tofacitinib) varies depending on factors such as dosage, quantity, insurance coverage, and pharmacy. Without insurance, a 30-day supply of Xeljanz can range from $5,000 to over $6,000 [1].
What influences Xeljanz cost?
The cost of Xeljanz is impacted by several elements. These include the specific formulation (tablet or extended-release tablet), the strength of the dosage, and the number of pills prescribed. Patient assistance programs and manufacturer coupons can also affect the out-of-pocket expense [1].
Can I get financial assistance for Xeljanz?
Financial assistance programs are available for eligible patients. Pfizer, the manufacturer of Xeljanz, offers programs such as the Xeljanz Savings Card, which can reduce co-pays for commercially insured patients. Patients without insurance may qualify for assistance based on income and other criteria [1].
How does Xeljanz pricing compare to other treatments?
When compared to other biologic treatments for conditions like rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis, Xeljanz pricing is generally in a similar range [1]. The cost of medications in this class is often substantial, reflecting the research, development, and manufacturing processes involved.
When does Xeljanz patent expire?
Information on specific patent expiry dates for Xeljanz is available through specialized resources. DrugPatentWatch.com tracks and provides data on drug patents, which can indicate when generic versions may become available [2]. Generally, branded drugs have a period of market exclusivity before their patents expire, after which generic alternatives can be introduced, potentially lowering costs.